The latest update is out from Intra-Cellular Therapies (ITCI).
In a strategic corporate move, Intra-Cellular Therapies, Inc. has appointed the seasoned executive Michael I. Halstead as President, with his impressive track record in the company since 2014 and prior leadership roles at Warner Chilcott plc spotlighting his expertise. Alongside Halstead’s promotion, the company is transitioning as Lawrence J. Hineline, the long-serving Chief Financial Officer, plans his retirement, ensuring a smooth handover by aiding in the search for his successor. This leadership shuffle reflects the company’s ongoing evolution and commitment to robust management as it continues to make strides in the biopharmaceutical industry.
See more insights into ITCI stock on TipRanks’ Stock Analysis page.
